3月3日，凯莱英跌2.05%，截至发稿，报92.50元/股，成交4.65亿元，换手率1.59%，总市值333.81亿 元。凯莱英股价已经连续4天下跌，区间累计跌幅7.07%。 摩根安通回报混合A（004361）成立日期2017年4月26日，最新规模1361.17万。今年以来收益2.8%，同 类排名5873/8892；近一年收益13.85%，同类排名5668/8141；成立以来收益60.69%。 摩根安通回报混合A（004361）基金经理为周梦婕。 从基金十大重仓股角度 数据显示，摩根基金旗下1只基金重仓凯莱英。摩根安通回报混合A（004361）四季度持有股数3500 股，占基金净值比例为1.24%，位居第五大重仓股。根据测算，今日浮亏损失约6790元。连续4天下跌 期间浮亏损失2.46万元。 截至发稿，周梦婕累计任职时间6年337天，现任基金资产总规模140.14亿元，任职期间最佳基金回报 37.22%， 任职期间最差基金回报1.71%。 声明：市场有风险，投资需谨慎。 本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本 文出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问 ...

Group 1 - Kailaiying's stock price increased by 1.32% to 105.87 CNY per share, with a trading volume of 977 million CNY and a turnover rate of 2.88%, resulting in a total market capitalization of 38.176 billion CNY [1] - The stock has risen for three consecutive days, with a cumulative increase of 5.49% during this period [1] - Kailaiying Pharmaceutical Group, established on October 7, 1998, and listed on November 18, 2016, primarily provides CMO pharmaceutical outsourcing services, with revenue composition of 76.19% from small molecule CDMO solutions, 23.71% from emerging services, and 0.10% from other sources [1] Group 2 - Newwo Fund has a significant holding in Kailaiying, with its Newwo Domestic Demand Growth Mixed A Fund (012143) reducing its position by 200 shares to hold 4,800 shares, representing 4.99% of the fund's net value, ranking as the ninth largest holding [2] - The fund has realized a floating profit of approximately 6,624 CNY today, accumulating a floating profit of 26,400 CNY during the three-day increase [2] - The Newwo Domestic Demand Growth Mixed A Fund was established on September 9, 2021, with a latest scale of 8.5055 million CNY, achieving a year-to-date return of 10.7% and a one-year return of 40.04% [2]

Core Viewpoint - Kailaiying's stock performance shows a slight increase, with significant trading activity and a notable balance in margin financing and securities lending, indicating investor interest and market dynamics [1][2]. Group 1: Stock Performance and Trading Activity - On January 6, Kailaiying's stock rose by 0.76%, with a trading volume of 384 million yuan [1]. - The margin financing data for January 6 indicates a financing buy amount of 43.63 million yuan and a financing repayment of 48.73 million yuan, resulting in a net financing outflow of 5.10 million yuan [1]. - As of January 6, the total margin financing and securities lending balance for Kailaiying was 913 million yuan, with the financing balance exceeding 50% of the one-year percentile level, indicating a high position [1]. Group 2: Company Financials and Shareholder Information - As of September 30, Kailaiying reported a total revenue of 4.63 billion yuan for the first nine months of 2025, reflecting a year-on-year growth of 11.82% [2]. - The net profit attributable to shareholders for the same period was 800 million yuan, showing a year-on-year increase of 12.66% [2]. - The number of shareholders increased to 60,100, a rise of 45.37% compared to the previous period [2]. Group 3: Dividend and Institutional Holdings - Kailaiying has distributed a total of 2.40 billion yuan in dividends since its A-share listing, with 1.70 billion yuan paid out in the last three years [2]. - Among the top ten circulating shareholders as of September 30, notable changes include an increase in holdings by China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited, while a decrease was observed in holdings by Huabao CSI Medical ETF [2].

Core Viewpoint - Kailaiying's stock price has shown a slight increase of 2.01% year-to-date, with fluctuations in trading volume and market capitalization, indicating a mixed performance in the short term [1] Group 1: Stock Performance - As of January 5, Kailaiying's stock price reached 94.80 yuan per share, with a trading volume of 1.10 billion yuan and a turnover rate of 0.37%, resulting in a total market capitalization of 34.184 billion yuan [1] - Year-to-date, Kailaiying's stock has increased by 2.01%, but it has decreased by 1.27% over the last five trading days, increased by 4.36% over the last 20 days, and decreased by 16.46% over the last 60 days [1] Group 2: Financial Performance - For the period from January to September 2025, Kailaiying achieved a revenue of 4.630 billion yuan, representing a year-on-year growth of 11.82%, and a net profit attributable to shareholders of 800 million yuan, reflecting a year-on-year increase of 12.66% [2] - Since its A-share listing, Kailaiying has distributed a total of 2.405 billion yuan in dividends, with 1.701 billion yuan distributed over the past three years [2] Group 3: Shareholder Structure - As of September 30, 2025, Kailaiying had 60,100 shareholders, an increase of 45.37% compared to the previous period, with an average of 0 circulating shares per shareholder [2] - Among the top ten circulating shareholders, notable changes include an increase in holdings by China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited, while a decrease was observed in holdings by Huabao Zhongzheng Medical ETF [2]

Core Viewpoint - Kailaiying's stock price has experienced fluctuations, with a year-to-date increase of 21.46% but a recent decline over various trading periods, indicating potential volatility in the market [1][2]. Financial Performance - For the period from January to September 2025, Kailaiying achieved a revenue of 4.63 billion yuan, representing a year-on-year growth of 11.82%. The net profit attributable to shareholders was 800 million yuan, reflecting a growth of 12.66% [2]. - Since its A-share listing, Kailaiying has distributed a total of 2.405 billion yuan in dividends, with 1.701 billion yuan distributed over the past three years [3]. Stock Market Activity - As of November 19, Kailaiying's stock price was 91.09 yuan per share, with a market capitalization of 32.846 billion yuan. The stock saw a trading volume of 185 million yuan and a turnover rate of 0.63% [1]. - The stock has been on the "龙虎榜" (a list of stocks with significant trading activity) once this year, with the last appearance on August 8, where it recorded a net buy of -180 million yuan [1]. Shareholder Information - As of September 30, 2025, Kailaiying had 60,100 shareholders, an increase of 45.37% from the previous period. The average number of circulating shares per person remained at 0 [2]. - The top shareholders include various funds, with notable increases in holdings from 中欧医疗健康混合A and 香港中央结算有限公司 [3].

Core Viewpoint - Kailaiying's stock price has experienced fluctuations, with a year-to-date increase of 29.29% but a recent decline of 11.92% over the past 60 days, indicating potential volatility in the market [1][2]. Financial Performance - For the period from January to September 2025, Kailaiying achieved a revenue of 4.63 billion yuan, representing a year-on-year growth of 11.82%. The net profit attributable to shareholders was 800 million yuan, reflecting a growth of 12.66% [2]. - Since its A-share listing, Kailaiying has distributed a total of 2.405 billion yuan in dividends, with 1.701 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of Kailaiying's shareholders reached 60,100, an increase of 45.37% compared to the previous period. The average circulating shares per person remained at 0 shares [2]. - The top ten circulating shareholders include notable funds such as China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited, with varying changes in their holdings [3]. Market Activity - On November 4, Kailaiying's stock price fell by 2.02%, trading at 96.96 yuan per share, with a total market capitalization of 34.963 billion yuan. The stock saw a net outflow of 3.0292 million yuan in principal funds [1]. - The stock has appeared on the "Dragon and Tiger List" once this year, with the most recent occurrence on August 8, where it recorded a net buy of -180 million yuan [1]. Business Overview - Kailaiying Pharmaceutical Group, established on October 7, 1998, and listed on November 18, 2016, primarily provides CMO pharmaceutical outsourcing services. The revenue composition includes 76.19% from small molecule CDMO solutions and 23.71% from emerging services [1][2]. - The company operates within the pharmaceutical and biotechnology sector, specifically in medical services and medical research outsourcing [2].

Group 1 - The core point of the news is that Kailaiying's stock price dropped by 5.2% to 97.20 CNY per share, with a trading volume of 260 million CNY and a turnover rate of 0.84%, resulting in a total market capitalization of 35.05 billion CNY [1] - Kailaiying Pharmaceutical Group (Tianjin) Co., Ltd. is located in Tianjin Economic and Technological Development Zone and was established on October 7, 1998, with its listing date on November 18, 2016 [1] - The company's main business involves providing CMO pharmaceutical outsourcing services, with revenue composition being 76.19% from small molecule CDMO solutions, 23.71% from emerging services, and 0.10% from other sources [1] Group 2 - From the perspective of fund holdings, Guotou Ruijin Fund has one fund heavily invested in Kailaiying, specifically the Guotou Ruijin Healthcare Mixed A Fund (000523), which held 40,700 shares in the third quarter, accounting for 3.21% of the fund's net value, ranking as the seventh largest holding [2] - The Guotou Ruijin Healthcare Mixed A Fund (000523) was established on February 25, 2014, with a latest scale of 129 million CNY, and has achieved a year-to-date return of 33.75%, ranking 2696 out of 8154 in its category [2] - The fund manager, Liu Zexu, has been in position for 2 years and 51 days, with a total asset scale of 243 million CNY, achieving a best return of 29.7% and a worst return of 19.71% during his tenure [2]

Core Insights - Kailaiying's stock increased by 5.27% on September 15, reaching a price of 117.99 CNY per share, with a trading volume of 1.247 billion CNY and a turnover rate of 3.43%, resulting in a total market capitalization of 42.546 billion CNY [1] Company Overview - Kailaiying Pharmaceutical Group (Tianjin) Co., Ltd. is located in Tianjin Economic and Technological Development Zone, established on October 7, 1998, and listed on November 18, 2016 [1] - The company's main business involves providing CMO (Contract Manufacturing Organization) pharmaceutical outsourcing services, with revenue composition as follows: 76.19% from small molecule CDMO solutions, 23.71% from emerging services, and 0.10% from other sources [1] Fund Holdings - According to data from the top ten holdings of funds, one fund under Jiashi Fund has a significant position in Kailaiying. Jiashi Healthcare Stock Fund (000711) held 387,100 shares in the second quarter, accounting for 4.14% of the fund's net value, ranking as the eighth largest holding [2] - The Jiashi Healthcare Stock Fund was established on August 13, 2014, with a latest scale of 825 million CNY. Year-to-date returns are 41.32%, ranking 748 out of 4222 in its category; the one-year return is 53.88%, ranking 1833 out of 3802; and since inception, the return is 131.9% [2] - The fund manager, Hao Miao, has been in position for 6 years and 244 days, with total assets under management of 3.652 billion CNY. The best fund return during his tenure is 183.83%, while the worst is -28.36% [2]

Investment Rating - The report assigns a "Buy" rating for the company, indicating a strong performance relative to the benchmark index [14]. Core Insights - The company shows a trend of accelerating performance with significant growth in both revenue and profit, supported by a robust order backlog [2]. - Emerging business segments are performing exceptionally well, contributing to overall revenue growth [5][6]. - The traditional small molecule CDMO business remains stable and profitable, with a solid project pipeline [3]. Summary by Sections Financial Performance - In H1 2025, the company achieved revenue of 3.188 billion yuan, a year-on-year increase of 18.20%, and a net profit of 617 million yuan, up 23.71% [1]. - For Q2 2025, revenue reached 1.647 billion yuan, reflecting a 26.94% year-on-year growth, while net profit increased by 33.94% to 291 million yuan [1]. Business Segments - The small molecule CDMO solutions generated revenue of 2.429 billion yuan in H1 2025, a 10.64% increase, accounting for 76.19% of total revenue [2]. - Emerging businesses reported revenue of 756 million yuan, a significant growth of 51.22%, making up 23.71% of total revenue [2]. Market Analysis - Domestic market revenue was 713 million yuan, growing 3.44%, while international market revenue reached 2.475 billion yuan, up 23.27% [2]. - Notably, revenue from European clients surged over 200%, indicating strong demand in that region [2]. Future Projections - The company anticipates continued growth in revenue and profit, with projected revenues of 6.71 billion yuan, 7.686 billion yuan, and 8.727 billion yuan for 2025, 2026, and 2027 respectively [8]. - The expected net profits for the same years are 1.108 billion yuan, 1.294 billion yuan, and 1.516 billion yuan [8].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Asymchem Laboratories (Tianjin) Co., Ltd. 凱萊英醫藥集團（天津）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6821） 海外監管公告 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第 13.10B 條作 出。 茲載列本公司在深圳證券交易所網站刊登的以下資料中文全文，僅供參閱。 承董事會命 凱萊英醫藥集團（天津）股份有限公司 Hao Hong博士 董事長、執行董事兼首席執行官 中國天津，二零二五年八月二十五日 於本公告日期，本公司董事會由董事長兼執行董事 Hao Hong 博士，執行董事楊蕊女 士、張達先生及洪亮先生，非執行董事 Ye Song 博士及張婷女士，以及獨立非執行董 事孫雪嬌博士、侯欣一博士及謝維愷先生組成。 【2025 年 8 月 26 日】 凯莱英医药集团（天津）股份有限公司 2025 年半年度报告全文 1 ...